RxDoctor Payments Data

Melissa White, NP

Adult Health · Johnson City, TNNPI 1114220472

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Medtronic at 38.7% of the total.

$4,793in general payments, 2019–2025

Across 318 payments — averaging $15.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Collegium Pharmaceutical, Inc.$1K
  • AbbVie$295
  • Nevro Corp.$279
  • Tersera Therapeutics LLC$262
  • Globus Medical$158
  • plus $738 from 13 others

What the payments were for

  • Food & beverage$4,781100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,793 in reported general payments places this provider in the 85th percentile of 352 adult health providers in Tennessee.

See all adult health providers in Tennessee

Medicare billing

Part B allowed, 2024
$74,950
Medicare patients
204
Services billed
914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl70$86,020
NucyntaTapentadol Hcl28$33,617
Xtampza ErOxycodone Myristate52$30,749
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,012$28,252
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen547$16,280
BelbucaBuprenorphine Hcl16$14,249
OxycontinOxycodone Hcl23$13,145
ZtlidoLidocaine16$12,800
Morphine Sulfate ErMorphine Sulfate332$11,476
Gabapentin629$9,732
LinzessLinaclotide14$9,524
Oxycodone Hcl520$8,674
Buprenorphine51$7,812
Oxymorphone Hcl ErOxymorphone Hcl12$6,765
ButransBuprenorphine12$6,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta, Xtampza Er, Belbuca$1,203$164,635166 claims
Scilex Pharmaceuticals Inc.Ztlido$134$12,80016 claims
AbbVieLinzess$295$9,52414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 352 adult health providers in Tennessee.

Other adult health in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →